8 results
Profiles of Antidiabetic Medications - AACE 2018 

#Antidiabetic #Medications #Profiles #SideEffects #Table #DecisionAid #Orals #DM2 #Diabetes
#SideEffects #Table ... #DecisionAid #Orals ... #DM2 #Diabetes ... #Endocrinology # ... Pharmacology #Management
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Diabetes Mellitus ... #Mellitus #DM2 ... #Medications #pharmacology ... #comparison #table ... #endocrinology
Metformin Pharmacology Summary
Mechanisms of Action:
 • Suppresses gluconeogenesis by the liver
 • Increases insulin-mediated glucose utilization
Metformin Pharmacology ... • Increases insulin-mediated ... Most effective oral ... #Summary #DM2 # ... diabetes #endocrinology
GLP-1 Agonists

Adlyxin (Lixisenatide) Daily
Bydureon (Exenatide ER) Weekly 
Ozempic (Semaglutide) Weekly 
Trulicity (Dulaglutide) Weekly 
Victoza (Liraglutide) Daily
to treat Type 2 Diabetes ... medications for insulin ... There is an ORAL ... GLP1 #Agonists #Pharmacology ... #DM2 #Endocrinology
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
Receptor Agonists - Pharmacology ... glucose-dependent insulin ... Ozempic), or daily tablet ... #Summary #DM2 # ... diabetes #endocrinology
DPP4 Inhibitors - Normal and Renal Dosing

Increase Incretins (GLP-I & GIP) -> Stimulates Insulin, Inhibits Glucagon
-> Stimulates Insulin ... DPP4 inhibitors work ... Renal #Dosing #Pharmacology ... #Management #Diabetes ... #DM2 #Endocrinology
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
Otherwise, it works ... drug to remain stable ... #semaglutide #Diabetes ... #Pharmacology # ... Endocrinology
Preoperative Risk Evaluation

Major Pre-Op Questions:
1. Does the patient have any modifiable risk factors that could be
complications from anesthesia ... neuroexam - Oral ... Insulin dependent ... DM ACS NSQIP: ... Diabetes regimen